» Articles » PMID: 32062769

Risk Factors of Ultrasound-detected Tophi in Patients with Gout

Overview
Journal Clin Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2020 Feb 17
PMID 32062769
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Tophus is a characteristic manifestation of advanced gout, the clinical significance of which is often underestimated. This study aimed to compare the difference of clinical and ultrasound features between gout patients with and without ultrasound-detected tophus and identify risk factors associated with the presence of ultrasonographic tophus in gout patients.

Materials And Methods: A total of 85 gout patients were divided into tophaceous (n = 54) and non-tophaceous group (n = 31) according to the presence of ultrasound-detected tophus. All patients underwent ultrasound examination of the bilateral knee, ankle, and first metatarsophalangeal joint (MTP1). Clinical information and ultrasound findings were compared between the groups. A multivariate logistic regression analysis to determine possible risk factors is associated with the number of ultrasound-detected tophaceous joints.

Results: Older age, longer gout duration, higher gout flare frequency, lower estimated glomerular filtration rate (eGFR), and higher prevalence of hypertension, hyperlipidemia, and ultrasound manifestations including double contour sign (DCS) and erosion were observed in tophaceous patients from the univariate analysis. Multivariable logistic regression analysis showed that eGFR and disease duration were independently associated with the number of tophaceous joints. Lower eGFR and longer course duration were associated with a higher risk of tophi (B = -0.020, 0.141; P = 0.009, 0.010, respectively).

Conclusions: The main factors that may influence the formation of tophi are disease duration and eGFR.Key Points• Lower eGFR and longer course duration are independent risk factors of tophi formation in gout patients.• The incidence of ultrasound manifestations including double contour sign (DCS) and erosion in patients with tophi were higher than those without tophi.

Citing Articles

[Gout : From the diagnosis to guideline-based treatment].

Bartsch V, Standfest K, Hueber A Z Gerontol Geriatr. 2025; 58(2):137-146.

PMID: 39998560 DOI: 10.1007/s00391-025-02416-6.


Revealing the potential bioactive components and mechanism of Qianhua Gout Capsules in the treatment of gouty arthritis through network pharmacology, molecular docking and pharmacodynamic study strategies.

Xiang G, Yang L, Qin J, Wang S, Zhang Y, Yang S Heliyon. 2024; 10(10):e30983.

PMID: 38770346 PMC: 11103544. DOI: 10.1016/j.heliyon.2024.e30983.


Clinical characteristics and risk factors associated with bone erosion in patients with tophi.

Ji Z, Huang Y, Liang L, Lin P, Guo X, Huang Q Adv Rheumatol. 2024; 64(1):18.

PMID: 38438904 DOI: 10.1186/s42358-023-00336-w.


Musculoskeletal Ultrasound Evaluates Renal Injury and Predicts Renal Outcome in Patients with Gout.

Li Z, He L, Jiao J, Jia J, Xing H, Zhou T Kidney Dis (Basel). 2023; 9(2):94-103.

PMID: 37065606 PMC: 10091006. DOI: 10.1159/000528200.


Establishment and Validation of Predictive Model of Tophus in Gout Patients.

Lei T, Guo J, Wang P, Zhang Z, Niu S, Zhang Q J Clin Med. 2023; 12(5).

PMID: 36902542 PMC: 10002994. DOI: 10.3390/jcm12051755.


References
1.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J . 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707. View

2.
Terkeltaub R . What makes gouty inflammation so variable?. BMC Med. 2017; 15(1):158. PMC: 5561591. DOI: 10.1186/s12916-017-0922-5. View

3.
Zhu Y, Pandya B, Choi H . Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125(7):679-687.e1. DOI: 10.1016/j.amjmed.2011.09.033. View

4.
Ma L, Sun R, Jia Z, Zou Y, Xin Y, Cheng X . Clinical characteristics associated with subcutaneous tophi formation in Chinese gout patients: a retrospective study. Clin Rheumatol. 2018; 37(5):1359-1365. DOI: 10.1007/s10067-017-3969-y. View

5.
Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites A, Pijoan J, Krishnan E . Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2013; 73(1):177-82. DOI: 10.1136/annrheumdis-2012-202421. View